Date: 2015-10-29
Type of information: Series A financing round
Company: InteRNA Technologies (The Netherlands)
Investors: INKEF Capital (The Netherlands) Aglaia Oncology Fund II (The Netherlands)
Amount: $ 10.5 million
Funding type: series A financing round
Planned used: InteRNA Technologies develops cancer therapeutics based on a broadly applicable proprietary technology platform for the rapid identification and validation of therapeutic miRNAs. At present, InteRNA has established in vivo proof of concept for multiple pipeline candidates. The proceeds of this financing will be used to progress several lead product candidates, through preclinical studies towards clinical development and for further expansion of the management team. InteRNA has miRNA compounds under development with proven pleiotropic effects across multiple oncogenic signaling pathways and cellular processes.
Others: * On October 29, 2015, InteRNA Technologies, a biopharma company engaged in the development of microRNA (miRNA)-based therapeutics for oncology, announces the closing of an equity financing round. This final extension of its Series A was co-led by new investors INKEF Capital and Aglaia Oncology Fund II. Existing shareholders also participated in this round, bringing the total Series A funding to US$ 10.5 million. In parallel to this funding, Hans Schikan, former CEO of Prosensa, has become the new chairman of InteRNA Technologies Supervisory Board. Further joining him and current member Mark Vaeck (CEO of Complix) on the Supervisory Board are Lucas de Breed and Karl Rothweiler for the new investors. The Board is further completed by Samuel Gerssen (for Waterman 40 Holding) and new independent member Brian Bronk (Sanofi Sunrise, part of the Sanofi Global R&D organization). InteRNA Technologies was incorporated by Aglaia Oncology Fund I as a spin-off from the Hubrecht Institute, Utrecht, the Netherlands.
Therapeutic area: Cancer - Oncology
